[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.5.239. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editor's Correspondence
September 25, 2000

Toward Better Therapy of Hypercholesterolemia—Reply

Arch Intern Med. 2000;160(17):2685-2686. doi:

In reply

We appreciate the comments from Dr Batalla and coworkers from Spain, who also observed a very high prevalence of elevated LDL cholesterol (>2.59 mmol/L [>100 mg/dL]) that persisted for more than 2 years following hospitalization for coronary heart disease.

On behalf of the GIFA study, Dr Sgadari points out the extreme paucity of lipid-lowering therapy (3%) in the cohort with coronary heart disease and elevated mean total cholesterol. Whether the lower rate of lipid-lowering therapy use in women is attributable to age-related differences between the sexes is an interesting question that unfortunately cannot be resolved in the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial1 owing to the relatively small number of participating women and associated lack of statistical power to formally test this hypothesis.

First Page Preview View Large
First page PDF preview
First page PDF preview
×